

Vimta Labs Limited

Registered Office
142, IDA Phase II, Cherlapally
Hyderabad-500 051, Telangana, India
T : +91 40 2726 4141
F : +91 40 2726 3657



VLL\SE\044\2025-26

Date: 17.07.2025

B S E Limited, P J Towers, Dalal Street, Mumbai - 400001. Scrip Code : 524394	National Stock Exchange of India Limited, "Exchange Plaza", Bandra, Kurla Complex, Bandra (E), Mumbai – 400051. Trading Symbol: VIMTALABS
--	--

Dear Sir/Madam,

Sub – Press Release – Unaudited Financial Results – 30th June 2025.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, please find attached the press release regarding the announcement of the unaudited Financial Results for the 1st Quarter ended 30th June 2025.

This is for your information and records.

Thanking you,

For VIMTA LABS LIMITED

Sujani Vasireddi
Company Secretary



Encl: as above.

Vimta Labs Limited Reports Q1 FY26 Results

Q1 FY26 Total Income at Rs. 993 Mn, 31.4% YoY
EBITDA margins at 35.7%; PAT margin at 19.0%

Hyderabad, July 17, 2025: Vimta Labs Limited (VIMTA) (BSE: 524394, NSE: VIMTALABS), India's leading Contract Research and Testing Organisation, has announced its financial results for the quarter ended June 30, 2025.

Financial Results – Q1 FY26:

Particulars (Rs. Mn)	Q1 FY26	Q4 FY25	QoQ (%)	Q1 FY25	YoY (%)	FY25	FY24	YoY (%)
Total Income	993	961	3.4%	756	31.4%	3482	2923	19.1%
EBITDA (including other income)	354	347	2.2%	266	33.1%	1262	978	29.1%
EBITDA Margin	35.7%	36.1%		35.2%		36.2%	33.4%	
PAT (continued operations)	189	183	3.1%	139	35.9%	668	488	36.8%
PAT Margin	19.0%	19.1%		18.4%		19.2%	16.7%	
Basic EPS	4.2	4.1	2.4%	3.1	33.8%	15.1	11.0	37.6%

Note: Vimta Labs sold its Diagnostic and Pathological services business to Thyrocare Technologies, as announced on August 30, 2024, with the transfer completed on October 11, 2024. Previous period figures for P&L have been regrouped to ensure comparability with the current period

Commenting on results, Ms. Harita Vasireddi, Managing Director, Vimta Labs Limited, said:

"We are happy to report a revenue of Rs. 993 Mn for the quarter which was driven by pharmaceutical & food contract research and testing services that we provide. I am pleased with the consistent progress Vimta continues to make in strengthening its service portfolio and deepening customer relationships across sectors.

Vimta completes a successful USFDA GCP inspection with zero Form 483 observations and received letter of cGMP compliance from ANSM (EMA) during the quarter. These outcomes are a reflection of Vimta's strong commitment to quality, and scientific rigor.

As a part of our efforts to enhance shareholder value, the Board has approved a Bonus issue in the ratio of 1:1, showcasing the company's strong financial position, confidence in future growth, and commitment to rewarding its shareholders.

Our focus remains on expanding our market reach and capabilities, fostering innovation, and creating sustainable long-term value for all our stakeholders."

Key Result Highlights for Q1 FY26:

Q1 FY26

- ✓ Total Income for Q1 FY26 was at Rs. 993 Mn
- ✓ EBITDA for Q1 FY26 was Rs. 354 Mn; EBITDA margin was at 35.7%
- ✓ PBT for Q1 FY26 was at Rs. 253 Mn
- ✓ Q1 FY26 PAT was at Rs. 189 Mn; PAT margin was at 19.0%
- ✓ Basic EPS in Q1 FY26 was Rs. 4.2

ABOUT VIMTA LABS LIMITED:

Founded in 1984 with headquarters in Hyderabad, India, VIMTA LABS LTD., is a leading contract research and testing organization, providing food, agri, bio/pharmaceutical, medical device, speciality chemical, and electronics companies an integrated scientific, technical, and regulatory expertise to support all stages of product development and manufacturing process. Vimta also provides environmental assessments and testing services.

CAUTIONARY STATEMENT:

This press release may contain certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Vimta Labs Limited has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

For details, please contact:

Investor Relations at Vimta Labs Siva Kambhampati (Chief Financial Officer) Siva.Kambhampati@Vimta.com Ernst & Young Siddesh Chawan Siddesh.Chawan@in.ey.com Advait Bhadekar Advait.bhadekar@in.ey.com	Registered Office Plot Number # 142, IDA Phase 2, Cherlapally, Hyderabad Telangana, India. 500051 CIN: L24110TG1990PLC011977 ISIN: INE579C01029 NSE Code: VIMTALABS BSE CODE: 524394 Website: www.vimta.com
---	--